Home › Compound Library › Eptinezumab (Vyepti)

Eptinezumab (Vyepti)

Biologicprescriptioniv · inferred

Humanized IgG1 monoclonal antibody targeting CGRP ligand, administered IV every three months for migraine prevention (100 mg or 300 mg IV q12 weeks). IV administration yields 100% bioavailability and rapid onset (within day 1 post-infusion). Biphasic PK with terminal half-life ~27 days. Well tolerated; nasopharyngitis and rare hypersensitivity reactions reported. Requires infusion center visit - borderline at-home vs clinic-administered tracking.

Projected serum levels — 100 mg, custom (shown daily)

Eptinezumab (Vyepti)
Eptinezumab (Vyepti) modeled serum levels, 100 mg custom (shown daily) over 121 days Population-based pharmacokinetic estimate. Steady state reached after approximately 73 days. 0 1.3k 2.5k 3.8k 5k Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule ≈ steady state · day 73
Eptinezumab (Vyepti) modeled serum levels with a loading dose of 300 mg, then 100 mg custom (shown daily) The first dose is larger so levels approach steady state faster. 0 1.3k 2.5k 3.8k 5k Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule

Maintenance schedule: 100 mg custom (shown daily) (iv).

Loading schedule: 300 mg on day 1, then 100 mg custom (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~73 days: peak ≈ 3.7k mg, trough ≈ 3.7k mg body load. Population-based estimate over 121 days for a 100 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Biologic
Route modeled
IV
Model confidence
inferred
Half-life
27 days
Common dose
100 mg
Suggested maximum
300 mg/day
Reference dose range
50–300 mg (single dose)
Suggested cadence
custom (shown daily)
Validated against
100 mg iv — Cmax 27 mg/L at 0.25 h

Documented interactions

  • watch
    Atogepant (Qulipta) + Eptinezumab (Vyepti) Stacked effects

    Atogepant (Qulipta) and Eptinezumab (Vyepti) both push the cgrp receptor in the same direction.

  • watch
    Erenumab (Aimovig) + Eptinezumab (Vyepti) Stacked effects

    Eptinezumab (Vyepti) and Erenumab (Aimovig) both push the cgrp receptor in the same direction.

  • watch
    Rimegepant (Nurtec ODT) + Eptinezumab (Vyepti) Stacked effects

    Eptinezumab (Vyepti) and Rimegepant (Nurtec ODT) both push the cgrp receptor in the same direction.

  • watch
    Ubrogepant (Ubrelvy) + Eptinezumab (Vyepti) Stacked effects

    Eptinezumab (Vyepti) and Ubrogepant (Ubrelvy) both push the cgrp receptor in the same direction.

Serum checks 4 modeled interaction pairings for eptinezumab (vyepti) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetics, safety, and tolerability of eptinezumab in patients with migraine Baker B et al. · Headache, 2020 DOI

    Clinical PK analysis establishing eptinezumab's ~27-day terminal half-life, IV bioavailability, and exposure-response relationship.

  2. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1) Ashina M et al. · Cephalalgia, 2020 DOI

    PROMISE-1 phase 3 trial demonstrating quarterly IV eptinezumab reduces monthly migraine days in episodic migraine.

2 published studies referenced in the app, each with a plain-language summary.